Lexicon Pharmaceuticals Inc
$ 2.47
4.66%
07 Aug - close price
- Market Cap 1,099,041,000 USD
- Current Price $ 2.47
- High / Low $ 2.48 / 2.29
- Stock P/E N/A
- Book Value 0.48
- EPS -0.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.40 %
- 52 Week High 2.68
- 52 Week Low 1.02
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Analyst Target Price
$3.86
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-07 | 2026-03-05 | 2025-11-06 | 2025-08-06 | 2025-05-13 | 2025-03-06 | 2024-11-12 | 2024-08-01 | 2024-05-02 | 2024-03-11 | 2023-11-08 |
| Reported EPS | -0.06 | -0.0026 | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.2 | -0.2 | -0.21 |
| Estimated EPS | -0.06 | -0.04 | -0.067 | -0.07 | -0.08 | -0.1 | -0.1248 | -0.17 | -0.19 | -0.2 | -0.23 | -0.22 |
| Surprise | 0 | 0.0374 | 0.027 | 0.03 | 0.09 | 0.03 | 0.0348 | -0.01 | 0.02 | 0 | 0.03 | 0.01 |
| Surprise Percentage | 0% | 93.5% | 40.2985% | 42.8571% | 112.5% | 30% | 27.8846% | -5.8824% | 10.5263% | 0% | 13.0435% | 4.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LXRX
2026-08-08 07:10:37
Piper Sandler has reiterated its Buy rating for Lexicon Pharmaceuticals (LXRX.US) and maintained its price target of $6. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-08-08 07:10:36
Wall Street Zen downgraded Lexicon Pharmaceuticals (NASDAQ:LXRX) to a "Sell" rating from "Hold," despite broader analyst consensus remaining "Hold" with an average price target of $4.55. The downgrade follows Lexicon missing Q2 earnings estimates, reporting a $0.06 loss per share and significantly lower revenue than expected. Despite the lowered rating and earnings miss, the company retains substantial institutional support and has potential future catalysts from its SONATA-HCM study and planned ZYNQUISTA resubmission.
2026-08-08 03:10:37
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a Q2 adjusted loss of $0.06 per share, missing analyst estimates by $0.01. Revenue significantly declined to $0.69 million from $28.9 million year-over-year, largely due to a prior-year licensing payment. Despite the financial miss, the company completed enrollment for its Phase 3 SONATA-HCM trial ahead of schedule and plans to resubmit the ZYNQUISTA NDA in Q4 2026, while maintaining strong liquidity.
2026-08-06 18:10:10
Lexicon Pharmaceuticals reported its second-quarter 2026 financial results, which included total revenues of $15.5 million and a net loss of $28.3 million. The company also provided updates on its clinical development programs, notably the successful completion of the Phase 2 RELIEF-DIA study for LX9200 in painful diabetic neuropathy. Lexicon ended the quarter with $82.5 million in cash and cash equivalents, projecting this to be sufficient to fund operations into the first half of 2027.
2026-08-06 14:42:03
FMR LLC filed an amended Schedule 13G, disclosing a beneficial ownership of 11.7% in Lexicon Pharmaceuticals, Inc. common stock, totaling 51,782,044.66 shares. Abigail P. Johnson also holds sole dispositive power over the same amount. Notably, Fidelity Growth Company Commingled Pool accounts for 5.6% of this stake, as of June 30, 2026.
2026-08-06 12:42:29
Lexicon Pharmaceuticals, Inc. (LXRX) reported Q2 revenue of $692,000, significantly missing the FactSet estimate of $4.0 million. The biopharmaceutical company also announced its Q2 2026 earnings call for August 6, 2026, and earnings results for the second quarter and six months ended June 30, 2026. This revenue report comes alongside news of the company's Q2 loss of $0.07 per share, which was also below the FactSet estimate.
